An observational study in Depressive Disorder, sponsored by Medical University of Gdansk. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Medical University of Gdansk · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Depressive Disorder with a site in Poland — 7 open to participants now, 7 under way, 2 of them phase 3. Depressive Disorder · Poland.
Among the 21 studies in Depressive Disorder with a site in Poland, this one is one of 3 that started in 2024, is the only observational one, and was the 17th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →7 of the 21 studies in Depressive Disorder with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in Poland, United States, Australia and 12 more countries
Ages 18–75
Seaport Therapeutics · Sites in Poland, United States, Bulgaria and 4 more countries
Ages 18–65
Jakub Antczak · Sites in Poland
Ages 18–65
Jakub Antczak · Sites in Poland
Ages 18–65
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 174 across 140 observational studies indexed under Depressive Disorder.
Median enrollment 600 across the 19 interventional studies, 150 across the 1 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Medical University of Gdansk is the lead sponsor of 133 studies on the registry; 46 are open to participants now.
Medical University of Gdansk has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06363981Jakub AntczakMultisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression | 2026-12 |
| NCT06371352Jakub AntczakEffect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression | 2026-12 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
| NCT07161700Seaport TherapeuticsAn Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Depressive Disorder with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.
Inpatients referred to the tertiary-reference unit for mood disorders with MDD or BD diagnosis, currently either with current depression or euthymic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis as provided by criteria:
Major depressive disorder (MDD) Bipolar disorder (BD)
Exclusion Criteria:
Diagnosis as provided by criteria:
Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD), as determined by a psychiatrist.
Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS)
Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
Also known as: 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)
The Maudsley 3-item Visual Analogue Scale (M3VAS)
To analyze internal consistency and factor analysis
Time frame: Baseline
16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)
To analyze convergent validity with The Maudsley 3-item Visual Analogue Scale (M3VAS)
Time frame: Baseline
Plan to share: Undecided
Started May 2024 (actual). Primary completion is estimated for Sep 2026, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Gdansk →